RxDoctor Payments Data

Carlo Bernardino, MD

Ophthalmic Plastic and Reconstructive Surgery · Salinas, CANPI 1770549412

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Amgen at 54.9% of the total. 2025 is the largest year on record at $165, more than ten times the $16 reported in 2021. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in CA, where the typical reported total is $1,399.

$361in general payments, 2019–2025

Across 13 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$198
  • Alcon$147
  • AbbVie$16

What the payments were for

  • Food & beverage$361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)11$198
Alcon1$147
AbbVie1$16

How this compares

$361 in reported general payments places this provider in the 10th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.

See all ophthalmic plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$455,211
Medicare patients
936
Services billed
4,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine31$40,849
Cyclosporine24$18,110
ErythromycinErythromycin Base483$4,907
TobradexTobramycin/Dexamethasone15$4,006
Prednisolone Acetate93$3,305
Doxycycline Hyclate46$1,799
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha143$1,638
Latanoprost22$277
Cephalexin12$88
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$81
Triamcinolone Acetonide27$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$16$40,84931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.

Other ophthalmic plastic and reconstructive surgery in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →